- Home
- KPRX vs DSS Comparison
KPRX vs DSS Comparison
Compare KPRX & DSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- DSS
- Stock Information
- Founded
- KPRX 1998
- DSS 1984
- Country
- KPRX United States
- DSS United States
- Employees
- KPRX N/A
- DSS N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- DSS Containers/Packaging
- Sector
- KPRX Health Care
- DSS Consumer Discretionary
- Exchange
- KPRX Nasdaq
- DSS Nasdaq
- Market Cap
- KPRX 8.3M
- DSS 8.0M
- IPO Year
- KPRX N/A
- DSS N/A
- Fundamental
- Price
- KPRX $3.18
- DSS $0.94
- Analyst Decision
- KPRX Strong Buy
- DSS
- Analyst Count
- KPRX 1
- DSS 0
- Target Price
- KPRX $10.00
- DSS N/A
- AVG Volume (30 Days)
- KPRX 10.5K
- DSS 14.0K
- Earning Date
- KPRX 05-09-2025
- DSS 05-13-2025
- Dividend Yield
- KPRX N/A
- DSS N/A
- EPS Growth
- KPRX N/A
- DSS N/A
- EPS
- KPRX 0.87
- DSS N/A
- Revenue
- KPRX $16,020,000.00
- DSS $19,097,000.00
- Revenue This Year
- KPRX N/A
- DSS N/A
- Revenue Next Year
- KPRX N/A
- DSS N/A
- P/E Ratio
- KPRX $3.56
- DSS N/A
- Revenue Growth
- KPRX N/A
- DSS N/A
- 52 Week Low
- KPRX $2.51
- DSS $0.77
- 52 Week High
- KPRX $5.76
- DSS $1.94
- Technical
- Relative Strength Index (RSI)
- KPRX 55.96
- DSS 50.52
- Support Level
- KPRX $2.64
- DSS $0.88
- Resistance Level
- KPRX $3.25
- DSS $1.00
- Average True Range (ATR)
- KPRX 0.19
- DSS 0.06
- MACD
- KPRX 0.06
- DSS 0.00
- Stochastic Oscillator
- KPRX 74.32
- DSS 55.56
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About DSS DSS Inc.
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia. Product packaging manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex three-dimensional direct mail solutions. Biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending through represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the securities trading and/or fund management arena.